Similarly, in the aristolochic acid (AA)-induced nephropathy model of kidney fibrosis, TNF-α inhibition using etanercept (ETN) for eight weeks reduced kidney inflammation and fibrosis, with significant suppression of IL-1β, IL-6, and collagen, suggesting TNF-α as an adjuvant for treating chronic kidney disease with fibrosis [48]. This evidence concerns the gene IL1B and chronic kidney disease.